DZ2640A1 - Composés thérapeutiquement actifs contenant de l'indazole en remplacement bio-isostérique du catéchol leur préparation et composition pharmaceutique les contenant. - Google Patents

Composés thérapeutiquement actifs contenant de l'indazole en remplacement bio-isostérique du catéchol leur préparation et composition pharmaceutique les contenant.

Info

Publication number
DZ2640A1
DZ2640A1 DZ980250A DZ980250A DZ2640A1 DZ 2640 A1 DZ2640 A1 DZ 2640A1 DZ 980250 A DZ980250 A DZ 980250A DZ 980250 A DZ980250 A DZ 980250A DZ 2640 A1 DZ2640 A1 DZ 2640A1
Authority
DZ
Algeria
Prior art keywords
catechol
bio
preparation
pharmaceutical composition
active compounds
Prior art date
Application number
DZ980250A
Other languages
English (en)
Inventor
Anthony Marfat
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DZ2640A1 publication Critical patent/DZ2640A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DZ980250A 1997-11-04 1998-11-03 Composés thérapeutiquement actifs contenant de l'indazole en remplacement bio-isostérique du catéchol leur préparation et composition pharmaceutique les contenant. DZ2640A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6402497P 1997-11-04 1997-11-04
US6422897P 1997-11-04 1997-11-04
US6419897P 1997-11-04 1997-11-04
US6422997P 1997-11-04 1997-11-04
US6418797P 1997-11-04 1997-11-04

Publications (1)

Publication Number Publication Date
DZ2640A1 true DZ2640A1 (fr) 2003-03-08

Family

ID=27535645

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ980250A DZ2640A1 (fr) 1997-11-04 1998-11-03 Composés thérapeutiquement actifs contenant de l'indazole en remplacement bio-isostérique du catéchol leur préparation et composition pharmaceutique les contenant.

Country Status (29)

Country Link
US (1) US6391872B1 (fr)
EP (1) EP1028946A1 (fr)
JP (1) JP2001521926A (fr)
CN (1) CN1284948A (fr)
AP (1) AP910A (fr)
AR (1) AR013746A1 (fr)
AU (1) AU754734B2 (fr)
BG (1) BG104450A (fr)
BR (1) BR9813926A (fr)
CA (1) CA2309150A1 (fr)
CZ (1) CZ20001621A3 (fr)
DZ (1) DZ2640A1 (fr)
EA (1) EA200000488A1 (fr)
HR (1) HRP20000253A2 (fr)
HU (1) HUP0004150A3 (fr)
ID (1) ID23921A (fr)
IL (1) IL135900A0 (fr)
IS (1) IS5465A (fr)
MA (1) MA26563A1 (fr)
NO (1) NO20002129L (fr)
NZ (1) NZ503918A (fr)
OA (1) OA11354A (fr)
PE (1) PE129199A1 (fr)
PL (1) PL340753A1 (fr)
SK (1) SK6252000A3 (fr)
TN (1) TNSN98200A1 (fr)
TR (1) TR200001234T2 (fr)
WO (1) WO1999023077A1 (fr)
YU (1) YU25000A (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1281441A (zh) * 1997-11-04 2001-01-24 辉瑞产品公司 以在pde4抑制剂中的儿茶酚的吲唑生物等排物置换为基础的治疗活性化合物
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
JP2001031549A (ja) * 1999-07-14 2001-02-06 Pola Chem Ind Inc 真皮コラーゲン線維束再構築剤及びそれを含有する化粧料
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
ES2272305T3 (es) * 1999-08-12 2007-05-01 Wyeth Holdings Corporation Composicion de contine un nsaid y un inhibidor de efgr cinasa para el tratamiento o la inhibicion de los polipos de colon y del cancer colorrectal.
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
US7005443B1 (en) * 2000-03-17 2006-02-28 Alcon, Inc. 5-Hydroxy indazole derivatives for treating glaucoma
BR0110302A (pt) 2000-04-18 2003-01-14 Agouron Pharma Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
WO2002083648A1 (fr) * 2001-04-16 2002-10-24 Eisai Co., Ltd. Nouveau compose a base de 1h-indazole
IL160271A0 (en) 2001-09-19 2004-07-25 Altana Pharma Ag Pharmaceutical compositions containing pde4-inhibitors and nsaid
WO2003024456A1 (fr) * 2001-09-20 2003-03-27 Eisai Co., Ltd. Methodes de traitement et de prevention des migraines
WO2003069740A2 (fr) * 2002-02-13 2003-08-21 Koninklijke Philips Electronics N.V. Dispositif optique a semi-conducteur integre, procede et appareil permettant de fabriquer ce dispositif
US7972632B2 (en) 2003-02-28 2011-07-05 Unigen Pharmaceuticals, Inc. Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors
US7108868B2 (en) 2002-03-22 2006-09-19 Unigen Pharmaceuticals, Inc. Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
US8034387B2 (en) 2002-04-30 2011-10-11 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
CA2703698C (fr) 2002-04-30 2016-11-22 Unigen Pharmaceuticals, Inc. Formulation pour un melange de flavonoides et de flavanes sans noyau b utilise comme agent therapeutique
JP4401298B2 (ja) 2002-12-02 2010-01-20 エフ．ホフマン−ラ ロシュ アーゲー Ｃｒｆアンタゴニストとしてのインダゾール誘導体
CN100422171C (zh) * 2003-02-14 2008-10-01 惠氏公司 作为5-羟色胺-6配体的杂环-3-磺酰基吲唑
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US20040220119A1 (en) * 2003-04-04 2004-11-04 Unigen Pharmaceuticals, Inc. Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
KR20060114022A (ko) 2004-02-27 2006-11-03 에프. 호프만-라 로슈 아게 인다졸 유도체 및 그들을 함유하는 약학 조성물
KR100844864B1 (ko) 2004-02-27 2008-07-09 에프. 호프만-라 로슈 아게 헤테로아릴-융합 피라졸로 유도체
US7844309B2 (en) * 2004-02-27 2010-11-30 Nokia Corporation Exchangeable keymat
CN1926139A (zh) 2004-02-27 2007-03-07 霍夫曼-拉罗奇有限公司 稠合吡唑衍生物
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
EA012245B1 (ru) * 2004-11-29 2009-08-28 УОРНЕР-ЛАМБЕРТ КОМПАНИ Эд-Эл-Си Терапевтические пиразоло[3,4-b]пиридины и индазолы
CA2619010C (fr) * 2005-08-15 2013-10-01 Wyeth Derives de 3-sulfonylindazole substitues en tant que ligands de 5-hydroxytryptamine-6
KR20080034497A (ko) * 2005-08-15 2008-04-21 와이어쓰 5-히드록시트립타민-6 리간드로서의 아지닐-3-설포닐인다졸유도체
JP2009506007A (ja) 2005-08-25 2009-02-12 エフ．ホフマン−ラ ロシュ アーゲー ｐ３８ＭＡＰキナーゼ阻害剤及びその使用方法
US7781460B2 (en) 2005-09-05 2010-08-24 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-IV
WO2007031838A1 (fr) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Pyrazolo[3,4-b]pyridines substituees en tant qu'inhibiteurs de la phosphodiesterase
AU2006311942B2 (en) * 2005-11-03 2012-11-22 Allergan, Inc. Prostaglandins and analogues as agents for lowering intraocular pressure
JP2009523734A (ja) 2006-01-13 2009-06-25 ワイス ５−ヒドロキシトリプタミン受容体のためのリガンドとしてのスルホニル置換された１ｈ−インドール
WO2007089646A1 (fr) 2006-01-31 2007-08-09 Array Biopharma Inc. Inhibiteurs de kinase et méthodes d'utilisation
US7829713B2 (en) 2006-02-28 2010-11-09 Helicon Therapeutics, Inc. Therapeutic piperazines
US8084485B2 (en) 2006-03-31 2011-12-27 Vitae Pharmaceuticals, Inc. 6-(aminoalkyl)indazoles
BRPI0709718A2 (pt) * 2006-04-05 2011-03-29 Wyeth Corp composto; método para tratamento de um transtorno do sistema nervoso central relacionado a ou afetado pelo receptor 5-ht6 em um paciente necessitado; composição farmacêutica; e proceso para a preparação do composto
WO2007120596A1 (fr) * 2006-04-12 2007-10-25 Wyeth DÉRIVÉS DE DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE EN TANT QUE LIGANDS DE 5-HYDROXYTRYPTAMINE-6
US8012886B2 (en) * 2007-03-07 2011-09-06 Asm Assembly Materials Ltd Leadframe treatment for enhancing adhesion of encapsulant thereto
SI2124944T1 (sl) 2007-03-14 2012-05-31 Ranbaxy Lab Ltd Derivati pirazolo b piridina kot inhibitorji fosfodiesteraze
US8558016B2 (en) * 2009-09-18 2013-10-15 Kabaushiki Kaisha Riverson Polyphenol derivative and method for producing the same
JP2013526542A (ja) 2010-05-12 2013-06-24 アッヴィ・インコーポレイテッド キナーゼのインダゾール阻害薬
CN103709146B (zh) * 2014-01-15 2015-11-25 中国药科大学 一类含苯并咪唑结构的喹啉-4-胺衍生物、其制法及医药用途
WO2021138391A1 (fr) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Composés d'indazole
MX2023007793A (es) 2020-12-30 2023-09-22 Tyra Biosciences Inc Compuestos de indazol como inhibidores de cinasas.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0338087A4 (en) * 1987-10-13 1991-07-24 Yoshitomi Pharmaceutical Industries, Ltd. Fused pyrazole compounds, process for their preparation, and their medicinal use
WO1989003385A1 (fr) * 1987-10-13 1989-04-20 Yoshitomi Pharmaceutical Industries, Ltd. Composes de pyrazole fusionnes, procede de preparation et utilisation en medecine
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
AP2001002304A0 (en) * 1996-05-03 2001-12-31 Pfizer Substituted indazole derivatives and related compounds
PL330974A1 (en) * 1996-06-25 1999-06-21 Pfizer Substituted derivatives of indazole and their application as inhibitors of phosphodiesterase (pde) of iv type and of tumor necrosis factor (tnf)
ATE211740T1 (de) * 1996-06-27 2002-01-15 Pfizer Substituierte indazolderivate
KR100338610B1 (ko) * 1996-09-04 2002-05-27 디. 제이. 우드, 스피겔 알렌 제이 인다졸 유도체 및 포스포디에스터라제 (pde) 유형 iv 및 종양괴사인자 (tnf) 생산의 억제제로서 그의 용도
CN1281441A (zh) * 1997-11-04 2001-01-24 辉瑞产品公司 以在pde4抑制剂中的儿茶酚的吲唑生物等排物置换为基础的治疗活性化合物

Also Published As

Publication number Publication date
US6391872B1 (en) 2002-05-21
NO20002129D0 (no) 2000-04-26
MA26563A1 (fr) 2004-12-20
HRP20000253A2 (en) 2001-06-30
TR200001234T2 (tr) 2000-08-21
HUP0004150A3 (en) 2001-08-28
JP2001521926A (ja) 2001-11-13
NO20002129L (no) 2000-07-03
OA11354A (en) 2003-12-23
AP9801375A0 (en) 1998-12-31
BR9813926A (pt) 2000-09-19
CA2309150A1 (fr) 1999-05-14
PL340753A1 (en) 2001-02-26
AR013746A1 (es) 2001-01-10
NZ503918A (en) 2002-03-28
AP910A (en) 2000-12-05
EP1028946A1 (fr) 2000-08-23
IL135900A0 (en) 2001-05-20
TNSN98200A1 (fr) 2005-03-15
WO1999023077A1 (fr) 1999-05-14
ID23921A (id) 2000-05-25
YU25000A (sh) 2003-12-31
EA200000488A1 (ru) 2000-10-30
CN1284948A (zh) 2001-02-21
SK6252000A3 (en) 2001-11-06
CZ20001621A3 (cs) 2001-08-15
AU9455298A (en) 1999-05-24
BG104450A (en) 2000-12-29
PE129199A1 (es) 1999-12-16
HUP0004150A2 (hu) 2001-05-28
AU754734B2 (en) 2002-11-21
IS5465A (is) 2000-04-19

Similar Documents

Publication Publication Date Title
MA26563A1 (fr) Composes therapeutiquement actifs contenant de l'indazole en remplacement bio-isosterique du catechol, leur preparation et composition pharmaceutique les contenant
FR2718136B1 (fr) Composés aromatiques aminés, procédé pour leur obtention et compositions pharmaceutiques les contenant.
DZ2128A1 (fr) Composés nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
CY2537B1 (fr) Composés hétérocycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant
DZ2045A1 (fr) Amides thérapeutiques, procédé pour leur préparation et compositions les contenant.
DZ2581A1 (fr) Dérivés d'acides aryloxyarylsulfonylaminohydroxamiques procédé pour leur préparation et compositionspharmaceutiques les contenant.
DZ2300A1 (fr) Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2299A1 (fr) Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2494A1 (fr) Composition pharmaceutique d'oméprazole.
EP0718287A3 (fr) Dérivés de pipérazine, médicaments les contenant, leur application, et procédés pour leur préparation
DZ2753A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tétrahydropyranne-4-carboxyliques) procédé pour leur préparation et compositions les contenant.
FR2711993B1 (fr) Médicaments contenant des dérivés de 7H-imidazol[1,2-a]pyrazine-8-one, les nouveaux composés et leur préparation.
DZ2890A1 (fr) 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2303A1 (fr) Dérivés d'indazole nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2465A1 (fr) Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions les contenant.
DZ2197A1 (fr) Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2523A1 (fr) Formulations pharmaceutiques contenant du voriconazole et procédé pour leur préparation.
DZ2697A1 (fr) Composés azapolycycliques à noyau aryle condensé procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2889A1 (fr) 4-Carboxyamino-2-méthyl-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositionspharmaceutiques les contenant.
DZ2887A1 (fr) Dérivés d'azétidine, leur préparation et les médicaments les contenant.
FR2708606B1 (fr) Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
DZ1957A1 (fr) Dérivés de pipéridine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2217A1 (fr) Dérivés d'imidazole substitués, procédé pour leur préparation et compositions les contenant.
DZ2550A1 (fr) Dérivés d'azétidinylpropylpipéridine procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2188A1 (fr) Dérivés de quinoxalinedone, procédés et intermédiaires pour leur préparation et compositions pharmaceutiques les contenant.